An oncolytic virus infected and killed both brain cancer stem cells and differentiated compartments of the common and deadly malignant brain tumor, glioblastoma multiforme (GBM), when combined with the immunosuppressant drug rapamycin.
Attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study.
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Fluorescence form 5-aminolevulinic acid (5-ALA) has been used to guide resection of recurrent GBM. Before surgery, the patient ingests 5-ALA, then the tumor cells fluoresce intraoperatively in response to certain wavelengths of light.
ELTD1, a protein linked with angiogenesis, is the strongest candidate for a significant association with glioma out of nearly 200 possible markers.
Patients with aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.
Glioblastoma multiforme tumors can originate not only from the glial cells that make up the supportive tissue of the brain and from neural stem cells, but also from other types of differentiated cells in the nervous system, including cortical neurons.
A controlled fasting period lasting no more than 48 hours improved the effectiveness of chemotherapy and radiation therapy in mice with gliomas.
Persons with more than one glioblastoma tumor upon diagnosis experience significantly worse survival than do patients with a solitary lesion.
A slower-growing set of glioblastoma multiforme cells appears to be the source of the brain cancer’s recurrence following standard drug therapy.
